Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...

In a significant move to alleviate the financial burden on patients, Finance Minister Nirmala Sitharaman announced in the ...

This follows the government’s decision in February 2024 to cut Goods and Services Tax (GST) on three key cancer ...

The government had earlier cut customs duties on Trastuzumab Deruxtecan, Osimertinib and Durvalumab from 10 per cent to nil ...

Custom Duty Exemption on life Saving Medicines in Budget 2025: This decision is part of a broader push to make essential healthcare more affordable, especially for cancer patients struggling with the ...

Finance Minister Nirmala Sitharaman announces Rs 98,311 crore allocation for healthcare, introducing daycare cancer centres, ...

Union Finance Minister Nirmala Sitharaman in her speech said that the budget primarily focused on the 'Garib (poor), Youth, ...

By focusing on increased funding, tax incentives, and support for domestic manufacturing, the government aims to make healthcare more accessible and affordable for all.

In July last year, after the Lok Sabha elections, the Health Ministry was allocated Rs 90958.63 crore in the Union Budget 2024-25.

The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, ...